BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/20/2015
Entire Document
 
11

 
 
Operating Results Comparison between Periods
 
Revenues and cost of revenues
 
See discussion under “Results of Operations - Overview” above.
 
Research and development expenses
 
   
Three months ended June 30,
   
Six months ended June 30,
 
   
2014
   
2015
   
Increase (decrease)
   
2014
   
2015
   
Increase (decrease)
 
   
(in thousands of U.S. dollars)
 
Research and development expenses, net
    2,792       2,891       99       5,511       6,102       591  

Comparison of three-month periods ending June 30, 2015 and 2014

Research and development expenses for the three months ended June 30, 2015 were $2.9 million, an increase of $0.1 million, or 4%, compared to $2.8 million for the three months ended June 30, 2014. The small increase resulted primarily from increased spending on BL-8040 in the 2015 period, partially offset by decreased spending on BL-7010, BL-9020 and BL-5010.

Comparison of six-month periods ending June 30, 2015 and 2014

Research and development expenses for the six months ended June 30, 2015 were $6.1 million, an increase of $0.6 million, or 11%, compared to $5.5 million for the six months ended June 30, 2014. The reason for the increase is similar to the one discussed above in the three-month comparison.

Sales and marketing expenses
 
   
Three months ended June 30,
   
Six months ended June 30,
 
   
2014
   
2015
   
Increase (decrease)
   
2014
   
2015
   
Increase (decrease)
 
   
(in thousands of U.S. dollars)
 
Sales and marketing expenses
    285       299       14       652       559       (93 )

Comparison of three-month periods ending June 30, 2015 and 2014

Sales and marketing expenses for the three months ended June 30, 2015 were $0.3 million, substantially similar to the comparable period in 2014.

Comparison of six-month periods ending June 30, 2015 and 2014

Sales and marketing expenses for the six months ended June 30, 2015 were $0.6 million, a decrease of $0.1 million, or 14%, compared to $0.7 million for the six months ended June 30, 2014. The decrease resulted primarily from professional fees related to a number of significant business development activities carried out during the six-month period in 2014, which resulted in collaboration and outlicensing agreements later in the year.